Cargando…

Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients

Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney transplant (KTX) recipients. In the current study, twelve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindemann, Monika, Baumann, Charleen, Wilde, Benjamin, Gäckler, Anja, Meller, Lara, Horn, Peter A., Krawczyk, Adalbert, Witzke, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227383/
https://www.ncbi.nlm.nih.gov/pubmed/35746452
http://dx.doi.org/10.3390/vaccines10060844
_version_ 1784734162089934848
author Lindemann, Monika
Baumann, Charleen
Wilde, Benjamin
Gäckler, Anja
Meller, Lara
Horn, Peter A.
Krawczyk, Adalbert
Witzke, Oliver
author_facet Lindemann, Monika
Baumann, Charleen
Wilde, Benjamin
Gäckler, Anja
Meller, Lara
Horn, Peter A.
Krawczyk, Adalbert
Witzke, Oliver
author_sort Lindemann, Monika
collection PubMed
description Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney transplant (KTX) recipients. In the current study, twelve female and 17 male KTX recipients were vaccinated twice with the adjuvanted, recombinant zoster vaccine Shingrix™, which contains the VZV glycoprotein E (gE). Cellular immunity against various VZV antigens was analyzed with interferon-gamma ELISpot. We observed the strongest vaccination-induced changes after stimulation with a gE peptide pool. One month after the second vaccination, median responses were 8.0-fold higher than the responses prior to vaccination (p = 0.0006) and 4.8-fold higher than responses after the first vaccination (p = 0.0007). After the second vaccination, we observed an at least twofold increase in ELISpot responses towards gE peptides in 22 out of 29 patients (76%). Male sex, good kidney function, early time point after transplantation, and treatment with tacrolimus or mycophenolate were correlated significantly with higher VZV-specific cellular immunity, whereas diabetes mellitus was correlated with impaired responses. Thus, our data indicate that vaccination with Shingrix™ significantly augmented cellular, VZV gE-specific immunity in KTX recipients, which was dependent on several covariates.
format Online
Article
Text
id pubmed-9227383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92273832022-06-25 Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients Lindemann, Monika Baumann, Charleen Wilde, Benjamin Gäckler, Anja Meller, Lara Horn, Peter A. Krawczyk, Adalbert Witzke, Oliver Vaccines (Basel) Article Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney transplant (KTX) recipients. In the current study, twelve female and 17 male KTX recipients were vaccinated twice with the adjuvanted, recombinant zoster vaccine Shingrix™, which contains the VZV glycoprotein E (gE). Cellular immunity against various VZV antigens was analyzed with interferon-gamma ELISpot. We observed the strongest vaccination-induced changes after stimulation with a gE peptide pool. One month after the second vaccination, median responses were 8.0-fold higher than the responses prior to vaccination (p = 0.0006) and 4.8-fold higher than responses after the first vaccination (p = 0.0007). After the second vaccination, we observed an at least twofold increase in ELISpot responses towards gE peptides in 22 out of 29 patients (76%). Male sex, good kidney function, early time point after transplantation, and treatment with tacrolimus or mycophenolate were correlated significantly with higher VZV-specific cellular immunity, whereas diabetes mellitus was correlated with impaired responses. Thus, our data indicate that vaccination with Shingrix™ significantly augmented cellular, VZV gE-specific immunity in KTX recipients, which was dependent on several covariates. MDPI 2022-05-26 /pmc/articles/PMC9227383/ /pubmed/35746452 http://dx.doi.org/10.3390/vaccines10060844 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lindemann, Monika
Baumann, Charleen
Wilde, Benjamin
Gäckler, Anja
Meller, Lara
Horn, Peter A.
Krawczyk, Adalbert
Witzke, Oliver
Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
title Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
title_full Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
title_fullStr Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
title_full_unstemmed Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
title_short Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
title_sort prospective, longitudinal study on specific cellular immune responses after vaccination with an adjuvanted, recombinant zoster vaccine in kidney transplant recipients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227383/
https://www.ncbi.nlm.nih.gov/pubmed/35746452
http://dx.doi.org/10.3390/vaccines10060844
work_keys_str_mv AT lindemannmonika prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients
AT baumanncharleen prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients
AT wildebenjamin prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients
AT gackleranja prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients
AT mellerlara prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients
AT hornpetera prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients
AT krawczykadalbert prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients
AT witzkeoliver prospectivelongitudinalstudyonspecificcellularimmuneresponsesaftervaccinationwithanadjuvantedrecombinantzostervaccineinkidneytransplantrecipients